- Home
- INAB vs SABS Comparison
INAB vs SABS Comparison
Compare INAB & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- SABS
- Stock Information
- Founded
- INAB 2016
- SABS 2014
- Country
- INAB United States
- SABS United States
- Employees
- INAB N/A
- SABS N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- INAB Health Care
- SABS Health Care
- Exchange
- INAB Nasdaq
- SABS Nasdaq
- Market Cap
- INAB 18.8M
- SABS 19.0M
- IPO Year
- INAB 2021
- SABS N/A
- Fundamental
- Price
- INAB $0.17
- SABS $1.25
- Analyst Decision
- INAB Strong Buy
- SABS Strong Buy
- Analyst Count
- INAB 2
- SABS 5
- Target Price
- INAB $3.60
- SABS $11.40
- AVG Volume (30 Days)
- INAB 1.1M
- SABS 38.1K
- Earning Date
- INAB 03-13-2025
- SABS 05-19-2025
- Dividend Yield
- INAB N/A
- SABS N/A
- EPS Growth
- INAB N/A
- SABS N/A
- EPS
- INAB N/A
- SABS N/A
- Revenue
- INAB N/A
- SABS $1,322,410.00
- Revenue This Year
- INAB N/A
- SABS N/A
- Revenue Next Year
- INAB N/A
- SABS $25.00
- P/E Ratio
- INAB N/A
- SABS N/A
- Revenue Growth
- INAB N/A
- SABS N/A
- 52 Week Low
- INAB $0.16
- SABS $1.11
- 52 Week High
- INAB $1.74
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- INAB 27.23
- SABS 31.17
- Support Level
- INAB $0.16
- SABS $1.11
- Resistance Level
- INAB $0.25
- SABS $1.80
- Average True Range (ATR)
- INAB 0.02
- SABS 0.16
- MACD
- INAB -0.01
- SABS -0.01
- Stochastic Oscillator
- INAB 9.77
- SABS 18.42
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.